bevacizumab
Development discontinued- Indications
- Cancer
Company intelligence / Profile preview
Centus Biotherapeutics
London, United Kingdompharmacompass.com ↗
- Ownership
- Private
- Development stage
- Dissolved
01
Overview
Centus successfully completed the AVANA Phase 3 clinical study demonstrating no clinically meaningful differences in safety, efficacy, and immunogenicity compared to Avastin® in non-small cell lung cancer patients. Their bevacizumab biosimilar Equidacent received European marketing authorization in September 2020.
- Therapeutic areas
- Oncology
- Modalities
- Biosimilarsmonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
AstraZenecaFujifilm Kyowa Kirin Biologics
Beyond the preview
Go deeper on Centus Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Centus Biotherapeutics.